News & Press Releases - Sarepta Therapeutics
Read news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine.
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the …
Jun 22, 2023 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jun. 22, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today …
Sarepta Therapeutics Announces U.S. FDA Acceptance of an …
Feb 16, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Feb. 16, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare …
Sarepta Therapeutics Announces Expanded US FDA Approval of …
Jun 20, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today …
Sarepta Therapeutics Announces That U.S. FDA has Accepted for …
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today …
Sarepta Therapeutics Announces Topline Results from EMBARK, a …
Oct 30, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today …
Press Releases - Sarepta Therapeutics, Inc.
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Sarepta Therapeutics | Biopharmaceutical Company for Rare …
Sarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. …
Sarepta Therapeutics Announces Sale of Priority Review Voucher …
Jul 5, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 5, 2023-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today …
Sarepta Therapeutics Submits Efficacy Supplement to Expand the …
Dec 22, 2023 · Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or …
- Some results have been removed